CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
Retrieved on:
Thursday, June 10, 2021
Alternative medicine, Retail, Health, Tobacco, Pharmaceutical, Biotechnology, Drugs, Psychoactive drugs, Entheogens, Euphoriants, Cannabis, Medicinal plants, Appetite stimulants, Antiemetics, Tetrahydrocannabinol, Cannabidiol, Medical cannabis, Effects of cannabis, CURE Pharmaceutical Holding Corp., Biopharmaceutical Research Company, CURE PHARMACEUTICAL HOLDING CORP., BIOPHARMACEUTICAL RESEARCH COMPANY
Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. Farm Bill.
Key Points:
- Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. Farm Bill.
- BRC will supply the ingredients and CURE will contribute its formulation development, regulatory, and commercial manufacturing capability, as well as support clinical studies.
- The partnership will initiate the development of CBD and Tetrahydrocannabinol (THC) oral thin films for CUREs clinical studies targeted at advancing veteran health.
- BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA.